201620152014 | 2013


Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Three cycles of epirubicin plus cyclophosphamide (EC) followed by docetaxel (EC-D) offered no survival benefits.

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Findings from a preclinical study of PI3K inhibitor taselisib's mechanism of action in mutant cell line and breast cancer xenograft models surprised researchers.

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Used alongside clinical variables, molecular prognostic signatures can identify postmenopausal women with ER+, HER2-negative breast cancer.

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA1 and BRCA2 mutation status predicts PFS in carboplatin-treated women with recurrent or metastatic triple-negative breast cancer (TNBC).

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

An orally-available formulation of proteolysis-targeting chimera (PROTAC) successfully degraded and reduced levels of estrogen-receptor alpha (ERα) protein.

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

Cancer drug prices will probably continue their steady climb.

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase inhibitor (AI) therapy is associated with endothelial dysfunction, a predictor of cardiovascular disease.

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

A biological risk profile can identify patients with ductal carcinoma in situ (DCIS) who are at high risk of recurrence and might benefit from radiotherapy.

Exercise and Gene Expression in Breast Cancer

Exercise and Gene Expression in Breast Cancer

Physical exercise might modulate the upregulation of immune and inflammatory-pathways involved in breast cancer.

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Subpopulations of tumor cells can form microanatomic associations with endothelial cells and macrophages.

Ki67 Suppression With Abemaciclib in Breast Cancer

Ki67 Suppression With Abemaciclib in Breast Cancer

Neoadjuvant therapy with the investigational oral CDK 4/6 inhibitor abemaciclib as monotherapy and with anastrozole reduced Ki67 levels.

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Adding the PI3K inhibitor buparlisib to fulvestrant endocrine therapy improves progression-free survival (PFS).

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating tumor microRNA signatures might discriminate between neoadjuvant chemotherapy-responsive and -unresponsive HER2+ breast cancers.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs